Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
about
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosingCardiovascular pharmacogenomics: current status and future directionsClopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Pharmacogenomics and cardiovascular diseaseClinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosingImpact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysisEffect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarinWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsWarfarin Pharmacogenetics: New Life for an Old DrugA genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin doseEstimation of the warfarin dose with clinical and pharmacogenetic data.10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal.Rapid genotyping of single nucleotide polymorphisms influencing warfarin drug response by surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF) mass spectrometry.Exploring genetic associations with ceRNA regulation in the human genome.Pharmacogenetics of warfarin: challenges and opportunities.Applied pharmacogenomics in cardiovascular medicineCYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacementComparative performance of gene-based warfarin dosing algorithms in a multiethnic population.Pharmacogenetics in Jewish populations.Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patientsNovel associations of VKORC1 variants with higher acenocoumarol requirements.Pharmacogenomics: the genetics of variable drug responses.Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.Cardiovascular pharmacogenomicsVariation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCXPersonalizing medicine with clinical pharmacogeneticsCopy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALUIdentification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation.Role of pharmacogenomics in the management of traditional and novel oral anticoagulantsFrequency of the cholesteryl ester storage disease common LIPA E8SJM mutation (c.894G>A) in various racial and ethnic groups.Pharmacogenetics and cardiovascular disease--implications for personalized medicineValidation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms.Thrombotic genetic risk factors and warfarin pharmacogenetic variants in São Miguel's healthy population (Azores)Integrative genomics strategies to elucidate the complexity of drug response.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Genomic architecture of pharmacological efficacy and adverse events.
P2860
Q24641999-6CC420FF-4506-4DB4-A2FE-01DB20E2FE84Q26801183-771A7657-0FC1-465C-A812-EE1A5FB3BC61Q26823542-DAEA4359-5252-4D78-9957-A351949AE4C9Q26997380-EF77817D-DD26-49DC-A454-C0798D4EE039Q27008360-617B63E5-A27D-4AD9-88E7-8635BAF9AADAQ28071310-4AED46EC-FB46-458D-A910-4DDA209C853EQ28276514-3EDE7372-1DB7-49AC-BFDB-D93B54DCCD58Q28395337-51B9E078-DF6D-44AB-A039-4295F8CECE45Q28468726-9FD0D59E-813A-408E-B2CC-CC65F4955801Q28475004-A4EEEF91-AA31-4D86-947D-D701E2EB8C07Q33410725-9EB1E3D2-772B-401D-9FBE-445A024D4A68Q33517162-3C6F0487-FE60-47A0-8096-217FCDA5D885Q33523960-BB999D50-BCEC-430E-BDD3-E9BA65A0103BQ33741112-5F62D972-A3E6-48C0-805B-87E935468DE6Q33819050-648D7B63-6AEB-4192-BC01-88AFEB5A3EF1Q33846255-4378A443-2BEC-4AC2-AA58-B0531C7362CAQ34026257-F8DB672B-E010-4414-A856-2A93EA5E0089Q34096562-AE29FFD1-BAEA-4CE9-AA3F-9B0EBF9FAFEAQ34458720-5AFA67DC-1F72-494E-8037-ECA8F5EE1FFFQ34571746-93C002E2-0242-4F3C-9000-AA8D7169DE0DQ34731671-6576867E-0443-4875-9301-E0F37E79D99EQ34976915-B641580B-EDCD-4F69-BF7A-BC4B05F240DDQ35110430-FE79FAAE-4735-4B68-8552-85BE2A38EC3BQ35447163-A6676BAA-7721-40C9-9AC1-28C9F4F83FB2Q35706472-A0C45AC8-93C0-495B-B97F-3F5903A988B2Q35791989-6ADC84D2-CA8C-489F-8CF3-7D5AA6582BDCQ35795982-1EB5CA5A-3409-424B-9A88-3C0CC66CDDC2Q35846595-9A1EB0A7-7FC6-440B-9E1E-DC69180AAA54Q36094919-309BE1BC-F75D-49CA-BDF9-3421CDB7C88FQ36219235-C7D729AF-195A-4369-AFF7-AF43E21F85C8Q36487290-CE45FD89-86CC-4336-93BE-2F0DDA17D684Q36631976-BA8EB1BA-6C87-401F-B032-0428D61756C0Q36848449-BBF58AFF-6BA3-43DB-B086-2673AC7D784DQ36948239-82697300-45DA-452D-8F14-4910658B049CQ36974672-EFC9D268-05AF-49C8-9CEE-11358BD3EB93Q37164469-275CE684-B3B2-4FFF-89D6-FA1BB183DC45Q37252967-9C63116E-78D8-451F-8C6D-FA84601FF492Q37961088-5D918E60-3635-4005-87C9-D17537B9C040Q38078754-8E2B5FC7-F188-49C1-B05C-9673951C5F1BQ38292930-59C4896C-10B7-4614-9F19-428007408187
P2860
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@ast
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@en
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@nl
type
label
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@ast
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@en
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@nl
prefLabel
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@ast
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@en
Warfarin pharmacogenetics: CYP ...... d Sephardi Jewish populations.
@nl
P2093
P2860
P1476
Warfarin pharmacogenetics: CYP ...... nd Sephardi Jewish populations
@en
P2093
Lisa Edelmann
Robert J Desnick
Ruth Kornreich
P2860
P304
P356
10.1016/J.AJHG.2007.10.002
P407
P577
2008-01-17T00:00:00Z